Recent insights in primary sclerosing cholangitis

被引：8

作者：

Ponsioen, Cyriel Y. ^{[1
]}

机构：

[1] Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1100 DE Amsterdam, Netherlands

来源：

JOURNAL OF DIGESTIVE DISEASES | 2012年 / 13卷 / 07期

关键词：

endoscopy; novel medical therapy; primary sclerosing cholangitis; DOSE URSODEOXYCHOLIC ACID; INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; NATURAL-HISTORY; NORURSODEOXYCHOLIC ACID; LIVER-TRANSPLANTATION; ENDOSCOPIC THERAPY; DUCT STRICTURES; PREVALENCE; RISK;

D O I：

10.1111/j.1751-2980.2012.00605.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the biliary tract leading to progressive obstruction, fibrosis and eventually liver cirrhosis. In some countries it ranks among the most frequent indications for liver transplantation. PSC is also a carcinogenic condition in which the risk of hepatobiliary carcinoma, especially cholangiocarcinoma, is greatly increased. Patients with associated inflammatory bowel disease involving the colon run an increased risk of colorectal carcinoma. Currently, there is no medical therapy with a proven benefit in halting disease progression.

引用

页码：337 / 341

页数：5

共 44 条

[21] MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease) [J].

Grant, AJ ;

Lalor, PF ;

Hübscher, SG ;

Briskin, M ;

Adams, DH .

HEPATOLOGY, 2001, 33 (05) :1065-1072

[22] Side Chain Structure Determines Unique Physiologic and Therapeutic Properties of norUrsodeoxycholic Acid in Mdr2-/- Mice [J].

Halilbasic, Emina ;

Fiorotto, Romina ;

Fickert, Peter ;

Marschall, Hanns-Ulrich ;

Moustafa, Tarek ;

Spirli, Carlo ;

Fuchsbichler, Andrea ;

Gumhold, Judith ;

Silbert, Dagmar ;

Zatloukal, Kurt ;

Langner, Cord ;

Maitra, Uday ;

Denk, Helmut ;

Hofmann, Alan F. ;

Strazabosco, Mario ;

Trauner, Michael .

HEPATOLOGY, 2009, 49 (06) :1972-1981

[23] Expression of the mucosal vascular addressin MAdCAM-1, in inflammatory liver disease [J].

Hillan, KJ ;

Hagler, KE ;

MacSween, RNM ;

Ryan, AM ;

Renz, ME ;

Chiu, HH ;

Ferrier, RK ;

Bird, GL ;

Dhillon, AP ;

Ferrell, LD ;

Fong, S .

LIVER, 1999, 19 (06) :509-518

[24] Novel biotransformation and physiological properties of norursodeoxycholic acid in humans [J].

Hofmann, AF ;

Zakko, SF ;

Lira, M ;

Clerici, C ;

Hagey, LR ;

Lambert, KK ;

Steinbach, JH ;

Schteingart, CD ;

Olinga, P ;

Groothuis, GMM .

HEPATOLOGY, 2005, 42 (06) :1391-1398

[25]

Hurlburt KJ, 2002, AM J GASTROENTEROL, V97, P2402, DOI 10.1111/j.1572-0241.2002.06019.x

[26] High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis [J].

Imam, M. H. ;

Sinakos, E. ;

Gossard, A. A. ;

Kowdley, K. V. ;

Luketic, V. A. C. ;

Harrison, M. Edwyn ;

McCashland, T. ;

Befeler, A. S. ;

Harnois, D. ;

Jorgensen, R. ;

Petz, J. ;

Keach, J. ;

DeCook, A. C. ;

Enders, F. ;

Lindor, K. D. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (10) :1185-1192

[27]

JOHNSON GK, 1987, GASTROINTEST ENDOSC, V33, P9

[28]

Kaya M, 2001, AM J GASTROENTEROL, V96, P1059

[29] Incidence and Prevalence of Primary Sclerosing Cholangitis in a Defined Adult Population in Sweden [J].

Lindkvist, Bjorn ;

de Valle, Maria Benito ;

Gullberg, Bo ;

Bjornsson, Einar .

HEPATOLOGY, 2010, 52 (02) :571-577

[30] High-Dose Ursodeoxycholic Acid for the Treatment of Primary Sclerosing Cholangitis [J].

Lindor, Keith D. ;

Kowdley, Kris V. ;

Luketic, Velimir A. C. ;

Harrison, M. Edwyn ;

McCashland, Timothy ;

Befeler, Alex S. ;

Harnois, Denise ;

Jorgensen, Roberta ;

Petz, Jan ;

Keach, Jill ;

Mooney, Jody ;

Sargeant, Carol ;

Bernard, Tamara ;

King, Debra ;

Miceli, Ellen ;

Schmoll, Jeff ;

Hoskin, Tanya ;

Thapa, Prabin ;

Enders, Felicity .

HEPATOLOGY, 2009, 50 (03) :808-814

← 1 2 3 4 5 →